Indraprastha Medical Corporation liquidity ratios

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Sep 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

9.05×	—	—	—	—	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
2.46×	2.46×	2.41×	1.86×	1.72×
2.41×	2.41×	2.37×	1.82×	1.66×
149	4.9	61.5	61.6	52.3
290	247	252	143	93.5

Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

alphave

INDRAMEDCO₹318.30

Indraprastha Medical Corporation Limited

· Pharma & Health

₹ CrorePeersARTEMISMED SHALBY GKSL GPTHEALTH LOTUSEYE DRAGARWQ KMCSHIL KOVAIMcap ₹2,918 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/09/2026
Altman Z-Score (Other Equity as RE)	—	—	—	—	9.05
Current Ratio	1.72	1.86	2.41	2.46	2.46
Quick Ratio	1.66	1.82	2.37	2.41	2.41
Cash, Equiv & ST Investments	52.3	61.6	61.5	4.9	148.6
Working Capital	93.5	142.6	252.4	247.0	290.1

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.